P2.03b-064 Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine
نویسندگان
چکیده
منابع مشابه
Personalized medicine for non-small-cell lung cancer.
Non-small-cell lung cancer (NSCLC) is a heterogeneous illness associated with a high mortality rate. Personalized therapy may improve treatment outcomes by identification of a specific genotypic anomaly and target-specific therapy. The most significant development in recent years was the discovery of activated EGF receptor (EGFR) mutations at exons 19 and 21. Patients with EGFR mutations respon...
متن کاملFuture of personalized medicine in non-small-cell lung cancer.
degradation or recycling. An ubiquitin lipase c-Cbl involved in internalization and degradation of the epidermal growth factor receptor (egfr) is frequently mutated or lost in lung cancer 1. Similarly, stress-activated kinases such as p38 have been implicated in egfr recycling and endosomal accumulation. Those events may contribute to resistance to antibody or tyrosine kinase inhibitors in the ...
متن کاملGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Lung cancer remains the leading cause of cancer-related mortality worldwide. The application of next-generation genomic technologies has offered a more comprehensive look at the mutational landscape across the different subtypes of non-small cell lung cancer (NSCLC). A number of recurrent mutations such as TP53, KRAS, and epidermal growth factor receptor (EGFR) have been identified in NSCLC. Wh...
متن کاملThe Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
Lung cancer is the leading cause of cancer-related mortality in Canada (1) and around the world. Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer, accounting for approximately 87% of cases and the majority of these are metastatic at the time of presentation (2, 3). We have reached a plateau (4, 5) with different systemic chemotherapies, specifically platinum-based, wh...
متن کاملAntiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
Over the past decade, patients with advanced non-small-cell lung cancer (NSCLC) have witnessed substantial advances in regards to therapeutic alternatives. Among newly developed agents, angiogenesis inhibitors were extensively tested in different settings and have produced some favorable outcomes despite several shortcomings. Bevacizumab is the most examined agent in this context and has demons...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1345